智飞生物(300122.SZ)：CA111注射液进入Ⅰ期临床试验

Core Viewpoint - The announcement highlights that Zhifei Biological (300122.SZ) has initiated Phase I clinical trials for its CA111 injection, developed by its subsidiary Chongqing Chen'an Biological Pharmaceutical Co., Ltd, indicating progress in its drug development pipeline [1] Group 1: Product Development - CA111 injection is a dual agonist targeting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which are crucial for insulin secretion and glucose homeostasis [1] - GIP is a 42-amino acid gastrointestinal regulatory peptide that stimulates insulin secretion from pancreatic beta cells in the presence of glucose and protects these cells [1] - GLP-1 is a 37-amino acid peptide that not only stimulates insulin secretion but also inhibits glucagon secretion, gastric emptying, and food intake, thereby controlling blood sugar and body weight [1] Group 2: Mechanism and Benefits - The dual receptor agonist approach of GIP and GLP-1 can achieve synergistic effects, enhancing glucose-lowering and weight loss efficacy compared to single-target drugs [1] - This synergistic mechanism may also help in reducing the side effects associated with administration, making it a potentially safer option for patients [1]